New Hampshire
Fee-For-Service Medicaid Coverage of Screening
Covered and Using Updated Guidelines
Highlighted Disparity
No racial disparities were found in New Hampshire for these lung cancer metrics.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 61.0 and significantly higher than the national rate of 54.6.
- New Hampshire ranks 36th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in New Hampshire improved by 18%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in New Hampshire is 28.9%, which is significantly higher than the national rate of 26.6%.
- It ranks 9th among the 42 states with survival data, placing it in the above average tier.
- Over the last five years, the survival rate in New Hampshire improved by 16%.
Early Diagnosis:
- 28.4% of cases are caught at an early stage, which is significantly higher than the national rate of 26.6%.
- It ranks 10th among the 47 states with data on diagnosis at an early stage, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in New Hampshire did not change significantly.
Lung Cancer Treatment
Surgical Treatment:
- New Hampshire ranked 5th (out of the 47 states with available data) with 18.4% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 20.8% and puts New Hampshire in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in New Hampshire did not change significantly.
Lack of Treatment:
- New Hampshire ranked 18th (out of the 47 states with available data) with 18.4% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.6% and puts New Hampshire in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in New Hampshire did not change significantly.
Screening
Screening for High Risk:
- In New Hampshire, 7.0% of those at high risk were screened, which was significantly higher than the national rate of 4.5%.
- It ranks 14th among all states, placing it in the above average tier.
- Actual screening rates may be higher in states with large, regional managed care providers that did not share screening data.
Medicaid Coverage:
- New Hampshire was one of the 49 states whose Medicaid fee-for-service programs covered lung cancer screening as of October 2023.
- However, they have not shown that their program uses the latest recommended guidelines for determining eligibility, and it was not known if it required prior authorization or copays.
Prevention
Tobacco Use:
- The smoking rate in New Hampshire is 12.3% and not significantly different than the national rate of 13.5%.
- It ranks 13th among all states, placing it in the average tier.
Radon:
- In New Hampshire, 35.3% of radon tests results were at or above the action level recommended by EPA.
- It ranks 36th among all states, placing it in the below average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 41.5 per 100,000 population among Black individuals in New Hampshire, not significantly different than the rate of 56.3 among Black individuals nationally, and not significantly different than the rate of 61.8 among white individuals in New Hampshire.
- Survival rates by race and ethnicity are not available for New Hampshire at this time. Nationally, the five-year survival rate among Black individuals is 23.8%, 11% lower than among white Americans.
- Other lung cancer rates are not available for Black individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- The rate of new lung cancer cases is 31.9 per 100,000 population among Latino individuals in New Hampshire, not significantly different than the rate of 28.2 among Latino individuals nationally, and significantly lower than the rate of 61.8 among white individuals in New Hampshire.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Latino individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 30.3 per 100,000 population among Asian or Pacific Islanders individuals in New Hampshire, not significantly different than the rate of 32.9 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 61.8 among white individuals in New Hampshire.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Asian or Pacific Islander individuals in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- Lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in New Hampshire due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in New Hampshire falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
New Hampshire has improved access to expanded screening by covering it through its fee-for-service Medicaid program. The Lung Association encourages all states to cover lung cancer screening based on the latest guidelines across all fee-for-service and managed care plans without any financial or administrative barriers in their Medicaid programs.
New Hampshire falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.